Production (Stage)
Kairos Pharma, Ltd.
KAPA
$0.475
$0.0020.42%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.58M | 1.92M | 1.73M | 1.62M | 1.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.32M | 2.34M | 1.98M | 1.89M | 1.88M |
| Operating Income | -3.32M | -2.34M | -1.98M | -1.89M | -1.88M |
| Income Before Tax | -3.54M | -2.60M | -2.74M | -2.01M | -1.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.54 | -2.60 | -2.74 | -2.01 | -1.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.54M | -2.60M | -2.74M | -2.01M | -1.99M |
| EBIT | -3.32M | -2.34M | -1.98M | -1.89M | -1.88M |
| EBITDA | -3.16M | -2.18M | -1.82M | -1.73M | -1.72M |
| EPS Basic | -0.27 | -0.22 | -0.26 | -0.19 | -0.19 |
| Normalized Basic EPS | -0.20 | -0.17 | -0.16 | -0.12 | -0.12 |
| EPS Diluted | -0.27 | -0.22 | -0.26 | -0.19 | -0.19 |
| Normalized Diluted EPS | -0.20 | -0.17 | -0.16 | -0.12 | -0.12 |
| Average Basic Shares Outstanding | 50.73M | 45.42M | 42.56M | 41.99M | 41.76M |
| Average Diluted Shares Outstanding | 50.73M | 45.42M | 42.56M | 41.99M | 41.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |